Literature DB >> 18538957

Beta-tryptase and quantitative mast-cell increase in a sudden infant death following hexavalent immunization.

Stefano D'Errico1, Margherita Neri, Irene Riezzo, Giuseppina Rossi, Cristoforo Pomara, Emanuela Turillazzi, Vittorio Fineschi.   

Abstract

The association between sudden infant death syndrome and immunization is frequently discussed. Serious adverse events following vaccination have generally been defined as those adverse events that result in permanent disability, hospitalization or prolongation of hospitalization, life threatening illness, congenital anomaly or death. They are generally referred to the inherent properties of the vaccine (vaccine reaction) or some error in the immunization process (programme error). The event could also be totally unrelated but only temporally linked to immunization (coincidental event). A fatal case of a 3-month-old female infant, who died within 24 h of vaccination with hexavalent vaccine is presented. Clinical data, post-mortem findings (acute pulmonary oedema, acute pulmonary emphysema), quali-quantitative data collected from immunohistochemical staining (degranulating mast cells) and laboratory analysis with a high level of beta-tryptase in serum, 43.3 microg/l, allows us to conclude that acute respiratory failure likely due to post hexavalent immunization-related shock was the cause of death.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538957     DOI: 10.1016/j.forsciint.2008.04.018

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  2 in total

Review 1.  Allergic reactions following contrast material administration: nomenclature, classification, and mechanisms.

Authors:  Cristian Palmiere; Lionel Comment; Patrice Mangin
Journal:  Int J Legal Med       Date:  2013-09-24       Impact factor: 2.686

Review 2.  Vaccination and anaphylaxis: a forensic perspective.

Authors:  Cristian Palmiere; Camilla Tettamanti; Maria Pia Scarpelli
Journal:  Croat Med J       Date:  2017-02-28       Impact factor: 1.351

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.